• Tumor-Targeted PAD4 Inhibitors Disrupt NETs for Antitumor Ef

  2026-06-03

  This study introduces phenylboronic acid-modified PAD4 inhibitors that achieve high tumor selectivity by targeting the PAD4-H3cit-NETs pathway in neutrophils. The research demonstrates robust in vivo antitumor activity with reduced toxicity, providing a foundation for next-generation PAD4 inhibitor design.

• 3X (DYKDDDDK) Peptide: Transforming Translational Proteomics

  2026-06-02

  This article explores the mechanistic and strategic advantages of the 3X (DYKDDDDK) Peptide for affinity purification, immunodetection, and structural studies, contextualized by recent advances in label-free interactome analysis and the evolving needs of translational researchers. Insights from leading studies and expert protocols demonstrate how this next-generation epitope tag is redefining the landscape for recombinant protein workflows.

• HDAC Inhibition as a Key Regulator of NUT Carcinoma Pathogen

  2026-06-02

  This study introduces a high-throughput chemical screen identifying diverse histone deacetylase (HDAC) inhibitors as potent repressors of NUT function in NUT carcinoma, a highly aggressive squamous cancer subtype. The findings reveal that HDAC inhibition disrupts oncogenic megadomains and induces differentiation in NUT carcinoma cells, providing mechanistic insights and therapeutic avenues for this treatment-resistant malignancy.

• Persistent rDNA Damage and PML-Nucleolar Compartment Dynamic

  2026-06-01

  This study reveals that topological stress and RNA polymerase I inhibition trigger persistent DNA lesions in ribosomal DNA, leading to the formation of PML-nucleolar associations (PNAs). The findings illuminate a specific pathway of genome surveillance and nucleolar reorganization, advancing our understanding of rDNA stability mechanisms with implications for cancer biology and cellular aging.

• Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repa

  2026-06-01

  This study uncovers how energy deficiency drives nuclear translocation of ATG4B, disrupting PRMT1-mediated DNA repair and accelerating acute myeloid leukemia progression. The findings establish a mechanistic link between cellular metabolism and genomic instability, opening new avenues for targeted therapeutic strategies in AML.

• Dimetridazole (BA1077): Reliable Antimicrobial for Lab Assay

  2026-05-31

  Dimetridazole (SKU BA1077) is a rigorously characterized nitroimidazole-class antimicrobial that supports reproducible bacterial culture assays, quorum sensing inhibition studies, and infection model research. This article presents scenario-driven guidance for optimizing cell-based and microbial workflows, comparing Dimetridazole’s data-backed performance and vendor reliability to common alternatives. APExBIO’s formulation is highlighted for its documented solubility, reactivity, and suitability in controlled investigations.

• Hydroxytyrosol in Oxidative Stress Modulation: Precision Res

  2026-05-30

  Explore Hydroxytyrosol as a potent antioxidant bioactive compound for advanced oxidative stress and cardiovascular health research. This article uniquely integrates mechanistic insights, product-specific protocols, and translational assay guidance beyond standard summaries.

• Veratridine as a Precision Probe: New Frontiers in Sodium Ch

  2026-05-29

  Explore how Veratridine, a potent voltage-gated sodium channel opener, is redefining sodium channel dynamics research and chamber-specific cardiomyocyte studies. This in-depth analysis uncovers unique scientific insights and advanced protocols for neuroscience and cardiac research.

• Technical Use of Angiotensin I/II (1-5) in RAS Research Work

  2026-05-29

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for modeling blood pressure regulation and aldosterone signaling within the renin-angiotensin system. It is indicated for cardiovascular and renal research but should not be applied in unrelated peptide or signaling studies due to its specific solubility and mechanistic scope.

• LY364947: TGF-β Type I Receptor Kinase Inhibitor in EMT & Fi

  2026-05-28

  LY364947 empowers researchers to dissect and modulate TGF-β-driven processes with precision, supporting advanced EMT, fibrosis, and retinal degeneration studies. This guide delivers actionable protocols, troubleshooting insights, and context from the latest pathway crosstalk research to maximize the impact of LY364947 in preclinical workflows.

• Optimizing Cell Viability Assessment: Translational Insights

  2026-05-28

  This thought-leadership article explores how advanced live-dead cell staining — specifically dual Calcein-AM and Propidium Iodide assays — is revolutionizing translational research in wound healing and biomaterials, bridging mechanistic understanding with actionable protocol guidance. It contextualizes the APExBIO Live-Dead Cell Staining Kit within the latest advances in diabetic wound therapy, comparing its precision and robustness to traditional methods, and offers strategic guidance for researchers seeking to maximize reproducibility and clinical relevance.

• Reliable Native Protein Gel Electrophoresis with Kit K4142

  2026-05-27

  This article delivers a scenario-driven, evidence-based guide to resolving common challenges in native protein gel electrophoresis for acidic proteins. Emphasizing the reproducibility and practical advantages of the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) (SKU K4142), it equips biomedical researchers and lab technicians with actionable insights for preserving native protein structure, enhancing data integrity, and streamlining experimental workflows.

• Fasudil (HA-1077) HCl: ROCK Inhibition Meets Hippo Pathway I

  2026-05-27

  Discover how Fasudil (HA-1077) HCl, a selective ROCK inhibitor, enables advanced research on cell proliferation and apoptosis by bridging Rho/ROCK and Hippo pathway biology. Explore mechanistic depth, assay optimization, and new translational avenues for cancer and lens research.

• Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma

  2026-05-26

  This study presents a nanoparticle system for systemic delivery of PTEN mRNA, effectively overcoming trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN expression and suppressing PI3K/Akt signaling, the approach offers a promising strategy for enhancing monoclonal antibody therapy efficacy.

• Methylation Pathways in Neurological Disorders: SAMe and Bey

  2026-05-26

  This review synthesizes evidence on the role of ademetionine (S-adenosylmethionine, SAMe) in methylation-dependent pathways relevant to neurological and psychiatric disorders. It details the mechanistic links between methyl group metabolism, neurotransmitter dynamics, and clinical outcomes, offering context for targeted intervention strategies in neuropsychiatric research.

8148 records 10/544 page Previous Next First page 上5页 678910 下5页 Last page